stars 1 stars 2 stars 3

View Aging (Aging-US)'s top competitors like Altos Labs, BioAge Labs, and Calico Life Sciences.

The Salk Institute is an independent, nonprofit research institute founded in 1960 by Jonas Salk, developer of the first safe and effective polio vaccine. The Institute’s mission is to drive foundational, collaborative, risk-taking research that addresses society’s most pressing challenges, including cancer, Alzheimer's disease, and agricultural vulnerability. This foundational science underpins all translational efforts, generating insights that enable new medicines and innovations worldwide. Learn more at www.salk.edu.
La Jolla, California, US
Education
$129.3M Revenue
http://www.salk.edu
1.2K Employees
Calico Life Sciences
Calico is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Calico’s highly innovative technology labs, its commitment to curiosity-driven discovery science and, with academic and industry partners, its vibrant drug-development pipeline together create an inspiring and exciting place to catalyze and enable medical breakthroughs. Calico is currently seeking exceptional candidates who share our passion for understanding the science of aging and developing therapeutics to address age-related diseases. Explore with us! https://www.calicolabs.com/careers
South San Francisco, California, US
Private
$42.3M Revenue
http://www.calicolabs.com/
496 Employees
Geron Corporation
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Driven by urgency and guided by purpose, we aim to help patients live with more energy, fewer limitations, and more possibility in everyday life. We bring together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care to pursue what’s next for patients. Our telomerase inhibitor is the first and only of its kind approved in the U.S. and EU for certain patients with lower-risk myelodysplastic syndromes (LR-MDS) and we continue to explore the potential of telomerase inhibition beyond LR-MDS, including in myelofibrosis and other cancers. Our culture is shaped by curiosity, collaboration, accountability and the persistence that has defined Geron from the beginning. The determination that helped transform telomerase inhibition from a bold scientific idea into a clinically validated approach continues to guide how we think, work, and pursue what’s next for patients. Learn more about our science, our people and opportunities to join #TeamGeron at www.geron.com Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/
Foster City, California, US
Public
$77M Revenue
http://www.geron.com
367 Employees
GERN Ticker
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users